Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Hepatitis C

  Free Subscription

Articles published in J Hepatol

Retrieve available abstracts of 97 articles:
HTML format

Single Articles

    August 2023
  1. DAI CY, Batsaikhan B, Huang CF
    'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison: some issues.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05050-X. doi: 10.1016/j.jhep.2023.

    July 2023
  2. MARTIN MT, Patel S, Chacra W
    Pellet-based hepatitis C virus treatment with glecaprevir/pibrentasvir: a case report of an adult with short bowel syndrome.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04997-8. doi: 10.1016/j.jhep.2023.

    June 2023
  3. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available

  4. THOMPSON LA, Plitt SS, Doucette K, Coffin CS, et al
    Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00419-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available

  5. PATEL S, Moser A, Domingo H
    Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
    J Hepatol. 2023 Jun 2:S0168-8278(23)00347-1. doi: 10.1016/j.jhep.2023.

    May 2023
  6. DENG H, Pan Y
    The influence of invasive procedures on acute HBV and HCV infections.
    J Hepatol. 2023 May 10:S0168-8278(23)00326-4. doi: 10.1016/j.jhep.2023.

    April 2023
  7. KONDILI LA, Rumi MG, Craxi A
    Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in Italy.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00310-0. doi: 10.1016/j.jhep.2023.

  8. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00309-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available

  9. SHEEHAN Y, Cunningham EB, Cochrane A, Byrne M, et al
    A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.
    J Hepatol. 2023 Apr 26:S0168-8278(23)00242-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available

  10. EL-KASSAS M, Emadeldeen M, Hassany M, Esmat G, et al
    A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00234-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available

  11. CROUCHET E, Baumert TF
    Unraveling the role of the liver myeloid compartment during hepatitis C virus cure.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00239-8. doi: 10.1016/j.jhep.2023.

    March 2023
  12. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.

  13. CAMINADA S, Mele A, Ferrigno L, Alfonsi V, et al
    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000-2021.
    J Hepatol. 2023 Mar 17:S0168-8278(23)00177-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available

  14. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
    J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.

    January 2023
  15. BURGER D, Aktas H, de Knegt R
    Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00027-2. doi: 10.1016/j.jhep.2023.

  16. MAALEJ NH, Collins IJ, Ades AE, Scott K, et al
    Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00014-4. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available

    December 2022
    Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series(') [J Hepatol 73 (2020) 1170-1218].
    J Hepatol. 2022 Dec 1:S0168-8278(22)03142-7. doi: 10.1016/j.jhep.2022.

    November 2022
  18. VAN DER PLUIJM RW, Smits LP, Rebers SP, Schinkel J, et al
    Unmasking of a hepatitis c genotype 3a/1b dual infection in an individual treated with elbasvir/ grazoprevir.
    J Hepatol. 2022 Nov 23:S0168-8278(22)03310-4. doi: 10.1016/j.jhep.2022.

    October 2022
  19. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    PubMed     Abstract available

    September 2022
  20. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    National trends in retreatment of HCV due to reinfection or treatment failure in Australia.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03118.
    PubMed     Abstract available

  21. OLTMANNS C, Liu Z, Mischke J, Tauwaldt J, et al
    Reverse Inflammaging: Long-term effects of HCV cure on biological age.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03115.
    PubMed     Abstract available

  22. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    PubMed     Abstract available

    August 2022
  23. DIETZ J, Mullhaupt B, Buggisch P, Graf C, et al
    Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    J Hepatol. 2022 Aug 25. pii: S0168-8278(22)03016.
    PubMed     Abstract available

    July 2022
  24. SEMMLER G, Meyer EL, Mandorfer M
    De-novo-HCC risk stratification after HCV-cure: All roads lead to Rome?
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02944.

  25. KARIMI-SARI H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK, et al
    Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02922.

    May 2022
  26. KUSHNER T, Djerboua M, Biondi MJ, Feld JJ, et al
    Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00331.
    PubMed     Abstract available

  27. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.

  28. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.

  29. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.

  30. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.

    March 2022
  31. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.

  32. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.

    February 2022
  33. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    PubMed     Abstract available

  34. LESLIE J, Geh D, Elsharkawy AM, Mann DA, et al
    Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00076.
    PubMed     Abstract available

    January 2022
  35. GALLARD C, Lebsir N, Khursheed H, Reungoat E, et al
    Heparanase is upregulated by HCV and favors its replication.
    J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00021.
    PubMed     Abstract available

  36. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.

  37. PIHL AF, Feng S, Offersgaard A, Alzua GP, et al
    Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02303.
    PubMed     Abstract available

    December 2021
  38. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    PubMed     Abstract available

  39. SEMMLER G, Meyer EL, Kozbial K, Schwabl P, et al
    HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02234.
    PubMed     Abstract available

    November 2021
  40. SANDUZZI-ZAMPARELLI M, Marino Z, Lens S, Sapena V, et al
    Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
    J Hepatol. 2021 Nov 29. pii: S0168-8278(21)02228.
    PubMed     Abstract available

    October 2021
  41. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    J Hepatol. 2021 Oct 8. pii: S0168-8278(21)02103.
    PubMed     Abstract available

  42. MALLET V, Beeker N, Bouam S, Sogni P, et al
    Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
    J Hepatol. 2021;75:848-855.
    PubMed     Abstract available

  43. WANG GP, Schnell GL, Kort JJ, Sidhu GS, et al
    Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    J Hepatol. 2021;75:820-828.
    PubMed     Abstract available

    September 2021
  44. CACOUB P, Comarmond C, Vieira M, Regnier P, et al
    HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02084.
    PubMed     Abstract available

  45. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    PubMed     Abstract available

    August 2021
  46. DO CARMO RF, de Souza CDF
    Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk?
    J Hepatol. 2021 Aug 23. pii: S0168-8278(21)01999.

    July 2021
  47. BORGIA SM, Shafran SD
    Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
    J Hepatol. 2021 Jul 19. pii: S0168-8278(21)01908.

  48. MONTALDO C, Terri M, Riccioni V, Battistelli C, et al
    Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.
    J Hepatol. 2021 Jul 13. pii: S0168-8278(21)01901.
    PubMed     Abstract available

    June 2021
  49. MARCOS-FOSCH C, Cabezas J, Crespo J, Buti M, et al
    Anti-epileptic drugs and hepatitis C therapy: real world experience.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00414.

  50. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
    Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
    PubMed     Abstract available

    Treatment failure with DAA therapy: Importance of resistance.
    J Hepatol. 2021;74:1472-1482.
    PubMed     Abstract available

    May 2021
  52. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed     Abstract available

  53. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
    Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.

  54. MATTHEWS GV, Bhagani S, Van der Valk M, Rockstroh J, et al
    Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
    J Hepatol. 2021 May 20. pii: S0168-8278(21)00336.
    PubMed     Abstract available

  55. SHAH R, Ahovegbe L, Niebel M, Shepherd J, et al
    Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
    J Hepatol. 2021 May 8. pii: S0168-8278(21)00310.
    PubMed     Abstract available

  56. CRESPO J, Diaz-Gonzalez A, Cabezas J
    HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
    J Hepatol. 2021 May 7. pii: S0168-8278(21)00308.

  57. REIG M, Cabibbo G
    Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).
    J Hepatol. 2021;74:1225-1233.
    PubMed     Abstract available

    April 2021
  58. DIETZ J, Sarrazin C
    Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00252.

  59. LLAMOSAS-FALCON L, Shield KD, Gelovany M, Hasan OSM, et al
    Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00253.
    PubMed     Abstract available

  60. SONNEVELD MJ, Veldhuijzen IK, van de Laar T, Op de Coul ELM, et al
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00250.

  61. DIETZ J, Di Maio VC, de Salazar A, Merino D, et al
    Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    J Hepatol. 2021;74:801-810.
    PubMed     Abstract available

    March 2021
  62. CRESPO J, Lazarus JV, Iruzubieta P, Garcia F, et al
    Let's leverage SARS-CoV2 vaccination to screen for hepatitis C screening in Spain, in Europe, around the world.
    J Hepatol. 2021 Mar 20. pii: S0168-8278(21)00181.

  63. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    PubMed     Abstract available

    February 2021
  64. MARTIN MT, Patel S, Kulik L, Chan C, et al
    Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
    J Hepatol. 2021 Feb 27. pii: S0168-8278(21)00158.

  65. CAPRARU C, Feld JJ
    Remaining challenges in HCV elimination.
    J Hepatol. 2021 Feb 12. pii: S0168-8278(20)33845.

  66. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    PubMed     Abstract available

    HCC surveillance after SVR in patients with F3/F4 fibrosis.
    J Hepatol. 2021;74:458-465.
    PubMed     Abstract available

    January 2021
  68. GIACOMELLI A, Pagani G, Conti F, Bassoli C, et al
    Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00009.

  69. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.

  70. LIU CH, Kao JH
    Reply to: "Sofosbuvir and the risk of kidney dysfunction".
    J Hepatol. 2021;74:257-258.

    December 2020
  71. BUTI M, Dominguez-Hernandez R, Casado MA
    Impact of the COVID 19 Pandemic on HCV Elimination in Spain.
    J Hepatol. 2020 Dec 20. pii: S0168-8278(20)33891.

  72. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.

  73. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.

  74. ZEUZEM S
    Introducing the HCV miniseries.
    J Hepatol. 2020;73:1306.

    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.

  76. NEGRO F
    Residual risk of liver disease after hepatitis C virus eradication.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33827.
    PubMed     Abstract available

    November 2020
  77. KUSHNER T, Reau N
    Changing epidemiology, implications, and recommendations for Hepatitis C in Women of Childbearing Age and During Pregnancy.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33814.
    PubMed     Abstract available

  78. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    PubMed     Abstract available

  79. Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues".
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33741.

  80. DAI CY, Chuang WL, Yu ML
    EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues.
    J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33693.

    Hepatitis C Viremic Organs in Solid Organ Transplantation.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33767.
    PubMed     Abstract available

  82. AQEL B, Wijarnpreecha K, Pungpapong S, Taner CB, et al
    Outcomes following transplantation of HCV-seropositive livers to HCV-seronegative recipients.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33754.
    PubMed     Abstract available

  83. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.

    October 2020
  84. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.

  85. CRESPO J, Diaz-Gonzalez A, Iruzubieta P, Llerena S, et al
    SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33679.

    September 2020
  86. THIMME R
    T cell immunity to hepatitis C virus: lessons for a prophylactic HCV vaccine.
    J Hepatol. 2020 Sep 28. pii: S0168-8278(20)33665.
    PubMed     Abstract available

  87. VIRZI A, Roca Suarez AA, Lupberger J
    Interferon revisited: Peering behind the lines of antiviral defense.
    J Hepatol. 2020;73:496-498.

    August 2020
  88. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.

    May 2020
  89. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut".
    J Hepatol. 2020;72:1036-1037.

  90. INNES HA, McDonald SA, Barclay ST, Irving WL, et al
    The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut.
    J Hepatol. 2020;72:1034-1035.

    February 2020
  91. VIBERT E, Schwartz M, Olthoff KM
    Advances in resection and transplantation for hepatocellular carcinoma.
    J Hepatol. 2020;72:262-276.
    PubMed     Abstract available

  92. SINGAL AG, Lampertico P, Nahon P
    Epidemiology and surveillance for hepatocellular carcinoma: New trends.
    J Hepatol. 2020;72:250-261.
    PubMed     Abstract available

    October 2019
  93. LAPOINTE-SHAW L, Austin PC, Chung H, Sander B, et al
    Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis.
    J Hepatol. 2019 Oct 21. pii: S0168-8278(19)30387.

    September 2019
  94. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    PubMed     Abstract available

    July 2019
  95. AVERHOFF F, Lazarus JV, Sergeenko D, Colombo M, et al
    Excellence in Viral Hepatitis Elimination - Lessons from Georgia.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30398.

    June 2019
  96. YAU T, Hsu C, Kim TY, Choo SP, et al
    Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis.
    J Hepatol. 2019 Jun 6. pii: S0168-8278(19)30300.
    PubMed     Abstract available

    March 2019
  97. FONTAINE H, Alric L, Labreuche J, Legendre B, et al
    Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    J Hepatol. 2019 Mar 9. pii: S0168-8278(19)30020.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.